secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2023-01-25T23:59:59+00:00
Accession:  0001420720-23-000004
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio appoints Dr. Martin Brenner as Interim CEO; Felipe Duran as Interim CFO
----------------------------------------------------------------------------

- Dr. Martin Brenner, previously CSO, appointed Interim CEO effective Jan. 20, 2023; receives $7,500/mo stipend plus 130,000 RSUs vesting over 12 months.
- Felipe Duran, previously VP FP&A, appointed Interim CFO effective Feb. 13, 2023; base salary increased from $300K to $350K, eligible for $140K special incentive bonus.
- Interim CEO appointment is temporary while board continues search for permanent CEO; Duran's additional retention bonus of $70K to remain through March 31, 2023.
- Both positions are at-will; severance includes 9 months base salary without cause, 12 months with change in control, plus COBRA and equity acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072023000004/0001420720-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072023000004/ibio-20230120x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer